FJFariha Javaid

Fariha Javaid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fariha Javaid has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acetylcholinesterase Inhibitory Potential and ADMET Analysis and Molecular Docking Studies of Coumarin and Benzohydrazide Derivatives in Alzheimer’s Disease

    by Naveed Muhammad, Sehrish Rehman, Abdur Rauf, Umer Rashid, Muhammad Umer Khan, Fariha Javaid, Arif Lodhi, Maha Munir, Haroon Khan, Yahya S. Al-Awthan, et al.

    Alzheimer’s disease (AD), a prevalent type of dementia, is an irreversible, progressive, neurodegenerative, age-related brain disease. It can be fatal and is characterized by acute behavioral abnormalities, including a decline in memory and cognitive abilities. AD is closely linked to acetylcholinesterase (AChEs), which degrades acetylcholine (ACh). By inhibiting AChE, the synaptic acetylcholine (ACh) level in the brain increases, reducing the symptoms of AD. Identifying more potent natural AChEIs is crucial for preventing the effects of AD. In this study, 28 coumarin and five benzohydrazide derivatives were examined against AChE using the microplate assay technique. The findings showed that, in comparison to the reference drug (IC[Formula: see text]M), two coumarin derivatives, compounds (CMP) 9 and 22, were effective inhibitors of AChE, with IC[Formula: see text] values of 354 ± 0.125 [Formula: see text]M and 430 ± 0.01 [Formula: see text]M, respectively. The two strong coumarin derivatives were subjected to molecular docking and ADMET analysis against human acetylcholinesterase, and CMP 9 and 22 showed excellent binding affinities with minimal energy values (−13 and − 11.4 kcal/mol). The two strong derivatives, CMP 9 and 22, are promising leads in the quest for effective AD medications because of their significant interactions with key residues in the AChE active site. Furthermore, animal model- and cell line-based verification is necessary to identify the long-term efficacy of these lead compounds.

  • Open Access

    In Silico Discovery of Cefoperazone as a Novel MMP-2 Inhibitor for Ovarian Cancer Therapy

    by Fariha Javaid, Sawaira Asim, Fariha Irshad, Nadia Mustafa, Emama Asif, Aroosa Akram, Masooma Ali, Tuba Farhat, Basmala Eslam

    In silico drug repurposing is a promising methodology to identify novel therapeutic applications for existing pharmaceuticals. This study explored the potential of eight third-generation cephalosporin antibiotics as matrix metalloproteinase-2 (MMP-2) allosteric inhibitors for selective targeting in ovarian cancer. MMP-2 is recognized for its pivotal role in tumor progression and metastasis, rendering it a compelling target for oncological treatment. We assessed the binding affinity and stability of selected cephalosporins with MMP-2 using molecular docking and molecular dynamics simulations. Our findings indicate that only Cefoperazone demonstrates robust binding interactions (ΔG -8.1 Kcal/mol) within the active site of MMP-2, suggesting its viability as an effective inhibitor. Molecular dynamics (MD) simulations using normal mode analysis (NMA) further revealed that the Cefoperazone-MMP-2 complex is exceptionally stable under virtual physiological conditions. Complex stability was supported by a low B-factor and a minimal eigenvalue (1.51×10−4). Elastic network model analysis indicated proper molecular mobility close to the binding site, with atoms connected by flexible springs. Consequently, these findings offer novel insights into cefoperazone as a potential candidate for MMP-2 inhibition in the treatment of ovarian cancer. This research validates in silico methodologies for drug repurposing and supports the development of targeted therapeutic strategies for ovarian cancer